June 29, 2017 / 4:20 PM / 24 days ago

BRIEF-Inventiva announces new compelling data on Odiparcil/IVA336

1 Min Read

June 29 (Reuters) - INVENTIVA SA:

* INVENTIVA ANNOUNCES NEW COMPELLING DATA ON ODIPARCIL/IVA336 TO BE PRESENTED AT MPS SOCIETY NATIONAL CONFERENCE

* ‍CONFIRMATION OF POTENTIAL TO BE FIRST ORALLY AVAILABLE SUBSTRATE REDUCTION THERAPY FOR MPS VI PATIENTS​

* ‍PHASE IIA IMPROVES CLINICAL STUDY SCHEDULED TO BEGIN BEFORE YEAR END 2017​

* PROFESSOR HENDRIKSZ WILL ALSO PRESENT DESIGN OF PLANNED PHASE IIA IMPROVES (IMPROVE MPS TREATMENT) CLINICAL STUDY

* PHASE IIA IMPROVES CLINICAL STUDY IS EXPECTED TO ENROLL ITS FIRST PATIENT BEFORE YEAR END Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below